UT-34 Inhibitor

Name: UT-34 Inhibitor; MyBioSource
Brand: MyBioSource
SKU: MBS5754088
Availability: InStock
Rating: 5 (10 reviews)

For Research Use Only. Not for use in diagnostic procedures. Catalog #: MBS5754088

UT-34 is a selective and orally active antagonist of second-generation pan-androgen receptor (AR) and degrader(IC50s of 211.7nM, 262.4nM and 215.7nM for wild-type, F876L and W741L AR, respectively), and has anti-prostate cancer efficacy. More details

Please Inquire

Product Documentation

Sample Manual Insert View PDF

Testing Data View PDF

Certificate of Analysis (COA) View PDF

QC Report View PDF

Material Safety Data Sheet View PDF

Technical Datasheet View PDF

Protocol View PDF

Product Overview

Online Datasheet in PDF

Product Name

UT-34, Inhibitor

Full Product Name

UT-34

Product Gene Name

UT-34, inhibitor

Form/Format

Solid. Powder

Purity/Purification

98.00%

Preparation and Storage

Store at -20 degree C for 3 years powder
-80 degree C for 2 years in solvent

Molecular Weight

356.27

Solubility

DMSO: 71mg/mL (199.29mM)
(<1mg/ml refers to the product slightly soluble or insoluble)

Formula

C15H12F4N4O2

SMILES

C[C@](O)(Cn1cc(F)cn1)C(=O)Nc1ccc(C#N)c(c1)C(F)(F)F

CAS Number

2168525-92-4

Target & IC50

Wild-type AR: ic50 211.7nM
F876L AR: ic50 262.4nM
W741L AR: ic50 215.7nM
androgen receptor

In Vitro

In NSG mice, UT-34 (20-40mg/kg; oral administration; daily; for 14 days) at 20 and 40mg/kg reduces the seminal vesicle weight by 10%-20% and 50%-60 %, respectively[1]. in rats,UT-34 inhibits androgen-dependent tissues such as prostate and seminal vesicles, and the growth of Enzalutamide-resistant castration-resistant prostate cancer (CRPC) xenografts. In intact immunocompromised rats, UT-34 also induces tumor regression [1].

Product Categories/Family for UT-34, inhibitor

Endocrinology/Hormones

Product References and Citations for UT-34, inhibitor

Ponnusamy S, et al. Orally Bioavailable Androgen Receptor Degrader, Potential Next-Generation Therapeutic for Enzalutamide-Resistant Prostate Cancer. Clin Cancer Res. 2019 Nov 15;25(22):6764-6780.
Ponnusamy S, et al. Orally Bioavailable Androgen Receptor Degrader, Potential Next-Generation Therapeutic for Enzalutamide-Resistant Prostate Cancer. Clin Cancer Res. 2019 Nov 15;25(22):6764-6780.
Stone L. UT-34: a promising new AR degrader. Nat Rev Urol. 2019 Nov;16(11):640.
Stone L. UT-34: a promising new AR degrader. Nat Rev Urol. 2019 Nov;16(11):640.

Other Notes

Small volumes of UT-34, inhibitor vial(s) may occasionally become entrapped in the seal of the product vial during shipment and storage. If necessary, briefly centrifuge the vial on a tabletop centrifuge to dislodge any liquid in the container`s cap. Certain products may require to ship with dry ice and additional dry ice fee may apply.

Searchable Terms for UT-34 purchase

MBS5754088 is an inhibitor targeting UT-34.